Who Owns Dermapharm Holding Company?

Who controls Dermapharm Holding?

Dermapharm Holding SE transitioned from a family-run German pharma to an IPO-listed group in 2018, fueling European expansion and vertical integration. Headquartered in Grünwald and founded in 1991, its strategy centers on branded, off-patent meds and selective acquisitions.

Ownership remains dominated by the Beier family, complemented by international institutions and a free float; as of early 2025 market cap ~2.4 billion EUR. See Dermapharm Holding Porter's Five Forces Analysis for strategic context.

Dermapharm was founded in 1991 by Wilhelm Beier, who held 100 percent ownership through family vehicles such as Themis Beteiligungs-AG, enabling a conservative, reinvestment-focused strategy that built manufacturing and R&D capacity before external financing.

Founder-led ownership

Wilhelm Beier retained full control via his family office and Themis Beteiligungs-AG, shaping early strategy and investment.

Concentrated equity

For roughly two decades the equity split remained unchanged, with no angel or private equity involvement.

Organic growth focus

Profits were reinvested into manufacturing and R&D, supporting steady expansion and bolt-on acquisitions.

Mittelstand-style governance

The company operated as a family-run entity with no documented ownership disputes or complex vesting.

Infrastructure buildout

Primary production at Brehna near Leipzig was established under family ownership and remains central.

IPO transition

Complex ownership emerged only ahead of the 2018 IPO; the Beier family ensured continued majority influence.

By the 2018 IPO the group already held over 900 marketing authorizations developed or acquired under family direction, and prior to listing the Beier family remained the dominant shareholder through Themis Beteiligungs-AG.

Key ownership facts

Founders and early ownership shaped Dermapharm’s corporate structure and investor relations ahead of public listing.

• Founder: Wilhelm Beier held 100% ownership initially via family vehicles.
• Primary vehicle: Themis Beteiligungs-AG served as the main family holding.
• Operational model: Profits reinvested into manufacturing and R&D; Brehna is a primary site.
• IPO: Ownership complexity rose approaching 2018, but the Beier family remained majority stakeholder.

For deeper details on how Dermapharm monetized its product portfolio and how ownership ties into revenue streams see Revenue Streams & Business Model of Dermapharm Holding.

Complete Dermapharm Holding Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Key events reshaping Dermapharm ownership include the IPO on February 9, 2018, initial valuation near 1.5 billion EUR, the Beier family retaining control via Themis Beteiligungs-AG, and the 2023 Arkopharma acquisition financed without major dilution of the family stake.

The current Dermapharm ownership profile reflects concentrated insider control combined with an active free float attracted by high EBITDA margins and steady dividends; institutional holders have gradually increased positions since 2020.

Major stakeholders and trends

Themis Beteiligungs-AG, the Beier family vehicle, is the anchor investor with a controlling 65.05% stake as of Q1 2025. The remaining free float is diversified among institutional and retail investors, with prominent funds holding modest single-digit stakes.

• Themis Beteiligungs-AG — 65.05% (majority, voting control)
• Free float — 34.95% (institutional and retail investors)
• Notable institutional holders: Allianz Global Investors, BlackRock Inc., Vanguard Group (each ~1.0%–3.5% range)
• EBITDA margins historically around 25%–30%, supporting investor interest

For additional context on market positioning and competitors relevant to Dermapharm ownership and strategy, see Competitors Landscape of Dermapharm Holding

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The current Board of Directors at Dermapharm Holding SE comprises a Supervisory Board chaired by founder Wilhelm Beier and a Management Board led by CEO Dr. Hans-Georg Feldmeier; the Supervisory Board mixes family representation and independent experts to oversee strategy and governance.

The governance structure reflects concentrated Dermapharm ownership: Themis Beteiligungs-AG controls 65.05% of voting rights, creating effective control at Annual General Meetings while voting remains one-share-one-vote; no dual-class or golden shares exist.

Board control and voting dynamics

The Supervisory Board chair represents the majority owner, aligning oversight with shareholder intent; operational independence is maintained by the Management Board.

• Majority voting power: 65.05% held by Themis Beteiligungs-AG
• One-share-one-vote standard; no special share classes
• Board appointments, dividends and capital changes effectively controlled by majority
• No recent major proxy fights; stable owner-management alignment

For context on corporate purpose and values that guide board decisions see Mission, Vision & Core Values of Dermapharm Holding; recent stability has supported strategic moves into herbal extracts and nutraceuticals and maintained dividend policies attractive to institutional holders.

Dermapharm Holding Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Between 2023 and early 2025 Dermapharm ownership shifted toward greater institutionalization within the free float, with the Beier family maintaining a 65% blocking stake while minority holders increasingly comprise ESG-integrated funds and international healthcare specialists.

Secondary market activity remained limited in 2024–2025 as the family pursued long-term holding, prioritized deleveraging after the Arkopharma acquisition, and invested in contract manufacturing ('Hergestellt für Andere') rather than share buybacks.

Ownership stability

Leadership continuity under Wilhelm Beier and a professionalized Management Board signal the family acting as steady stewards rather than daily operators.

Investor profile shift

ESG-integrated funds and international healthcare specialists now represent a growing share of Dermapharm major shareholders, improving the stock’s investor base.

Strategic priorities

Post-acquisition focus on deleveraging and expanding contract manufacturing capacity has outweighed capital return programs through 2025.

M&A prospects

Despite consolidation in European mid-cap pharma and occasional speculation, the 65% stake makes friendly deals contingent on founder consent and hostile bids infeasible.

Analysts expect Dermapharm Holding Company owner structure to remain static near-term, supporting predictability for investors seeking exposure to the resilient German pharmaceutical market; see further context in Growth Strategy of Dermapharm Holding.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE